新光药业(300519) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥96,123,097.26, representing a 35.83% increase compared to ¥70,769,147.70 in the same period last year[7] - Net profit attributable to shareholders was ¥38,981,195.06, up 42.77% from ¥27,303,243.40 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥38,515,154.50, reflecting a 44.96% increase from ¥26,568,702.40 in the previous year[7] - Basic earnings per share were ¥0.24, up 41.18% from ¥0.17 in the previous year[7] - Net profit for Q1 2021 was ¥38,981,195.06, reflecting a growth of 42.77% year-on-year[19] - Earnings per share for Q1 2021 was ¥0.24, up from ¥0.17 in the same period last year[19] - The operating profit for the first quarter was CNY 45,867,233.88, up from CNY 32,129,555.65, indicating a growth of 42.5% year-over-year[39] - The company reported a total comprehensive income of CNY 39,104,856.91 for the first quarter, compared to CNY 27,241,899.47 in the same period last year, an increase of 43.5%[40] Cash Flow and Assets - The net cash flow from operating activities reached ¥56,425,426.74, a significant increase of 57.79% compared to ¥35,758,819.24 in the same quarter last year[7] - Cash inflow from operating activities totaled ¥103,705,769.14, a rise of 30.41% compared to the previous year[18] - The company's cash and cash equivalents decreased to CNY 573,136,890.10 as of March 31, 2021, down from CNY 591,847,788.22 at the end of 2020[34] - The company reported a significant increase in trading financial assets, rising to CNY 150,000,000.00 from CNY 85,000,000.00[34] - The company experienced a net decrease in cash and cash equivalents of CNY 18,710,898.12 during the quarter, contrasting with an increase of CNY 17,031,246.77 in the previous year[44] Investments and Projects - The company established a wholly-owned subsidiary in Hangzhou to enhance R&D capabilities and reduce costs, utilizing part of the raised funds[21] - The total amount of raised funds is 21,167 million CNY, with 997.11 million CNY invested in the current quarter[25] - The cumulative amount of changed use of raised funds is 3,500 million CNY, accounting for 16.54% of the total raised funds[25] - The investment progress of the "Annual Production of 220 Million Bottles of Huangqi Shengmai Drink GMP Production Line" project is 64.49% as of June 30, 2019[25] - The company has allocated CNY 3,286.48 million for the establishment of a modern Chinese medicine research and development center[27] - The company has decided to change the investment nature of the "Regional Marketing Network Construction Project" to self-owned funds due to changes in the pharmaceutical industry policies[26] - The "Modern Chinese Medicine Research and Development Center" project is expected to enhance the company's core competitiveness and sustainable profitability[26] Liabilities and Equity - Total assets at the end of the reporting period were ¥928,879,474.84, an increase of 4.28% from ¥890,785,680.47 at the end of the previous year[7] - Net assets attributable to shareholders increased by 4.73% to ¥866,047,571.11 from ¥826,942,714.20 at the end of the previous year[7] - The total liabilities decreased slightly to CNY 62,831,903.73 from CNY 63,842,966.27[36] - The company's retained earnings increased to CNY 458,981,171.09 from CNY 419,999,976.03, reflecting a growth of 9.3%[37] Research and Development - Research and development expenses increased by 42.30% to ¥3,397,403.34 in Q1 2021, indicating a focus on innovation[18] - The company aims to improve product R&D efficiency and reduce costs by relocating drug R&D and registration work to the new center in Hangzhou[26] Risks and Challenges - The company faced potential risks related to local government policies and administrative approvals for the new subsidiary, which will be closely monitored[21] - The company reported a tax expense of CNY 6,886,038.82 for the quarter, which is an increase from CNY 4,826,312.25 in the previous year, reflecting a growth of 42.6%[39]